Quotient welcomes Thomas Aebischer to its Board of Directors

– SWITZERLAND, Eysins –  Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to its Board of Directors, effective on May 1, 2022.

“We are delighted to welcome Mr. Aebischer to the Quotient Board. Thomas brings decades of experience in global financial and capital markets and a highly strategic mindset. We are very fortunate to have him by our side as we continue to grow our business and drive the value of our revolutionary diagnostic solutions,” said Board Chairman, Heino von Prondzynski.

Thomas Aebischer will also join the Audit Committee.

About Thomas Aebischer

Mr. Thomas Aebischer has been CFO of RWDC Ltd., a biotechnology company concentrated on innovative and cost-effective environmentally friendly biopolymer material solutions, since March 2021. From January 2016 to December 2019, Mr. Aebischer served as Executive VP and CFO of LyondellBasell Industries, a company active in plastics, chemicals, and refinement. Mr. Aebischer also served as CFO for the Holcim Group from 2011 to 2015. Before becoming CFO, he worked in various positions for Holcim including as CFO for group companies from 1996 to 2010. Earlier in his career, Mr. Aebischer held positions as tax assessor and financial auditor. Mr. Aebischer has served as a director and member of the audit committee of Dormakaba (Switzerland) since October 2021.

Mr. Aebischer is a Swiss Certified Accountant and graduated from the Advanced Management Program at Harvard Business School.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that it believes reshape the way diagnostics are practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings for laboratories around the world. Quotient’s operations are based in Switzerland, Scotland, and the US.

The Quotient logo, Quotient MosaiQ, and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

For more information : https://www.quotientbd.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team